Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global gene expression and Stromal contents improve prognostic power in PMP patients treated by CRS+HIPEC

ABSTRACT: Global gene expression and Stromal contents improve prognostic power in PMP patients treated by CRS+HIPEC

PROVIDER: PRJNA616327 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Global gene expression and Stromal contents improve prognostic power in PMP patients treated by CRS+HIPEC

Project description:In recent years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have substantially improved the clinical outcome of pseudomyxoma peritonei (PMP) originating from mucinous appendiceal cancer. However, current histopathological grading of appendiceal PMP frequently fails in predicting disease outcome. We recently observed that the integration of cancer cell transcriptional traits with those of cancer-associated fibroblasts (CAFs) improves prognostic prediction for tumors of the large intestine. We therefore generated global expression profiles on a consecutive series of 24 PMP patients treated with CRS plus HIPEC. Multiple lesions were profiled for nine patients. We then used expression data to stratify the samples by a previously published "high-risk appendiceal cancer" (HRAC) signature and by a CAF signature that we previously developed for colorectal cancer, or by a combination of both. The prognostic value of the HRAC signature was confirmed in our cohort and further improved by integration of the CAF signature. Classification of cases profiled for multiple lesions revealed the existence of outlier samples and highlighted the need of profiling multiple PMP lesions to select representative samples for optimal performances. The integrated predictor was subsequently validated in an independent PMP cohort. These results provide new insights into PMP biology, revealing a previously unrecognized prognostic role of the stromal component and supporting integration of standard pathological grade with the HRAC and CAF transcriptional signatures to better predict disease outcome.

2021-03-21 | GSE147762 | GEO

Panicum hallii cultivar:CRS.3.G3

Project description:Panicum hallii CRS.3.G3 Transcriptome - CRS.3.G3.MIX_PacBio

| PRJNA1362274 | ENA

Panicum hallii cultivar:CRS.3.G3

Project description:Panicum hallii CRS.3.G3 Transcriptome - CRS.3.G3.P_Illumina

| PRJNA1360313 | ENA

Panicum hallii cultivar:CRS.3.G3

Project description:Panicum hallii CRS.3.G3 Transcriptome - CRS.3.G3.L_PacBio

| PRJNA1360094 | ENA

Panicum hallii cultivar:CRS.3.G3

Project description:Panicum hallii CRS.3.G3 Transcriptome - CRS.3.G3.L_Illumina

| PRJNA1360115 | ENA

Panicum hallii cultivar:CRS.3.G3

Project description:Panicum hallii CRS.3.G3 Transcriptome - CRS.3.G3.S_Illumina

| PRJNA1360211 | ENA

Panicum hallii cultivar:CRS.3.G3

Project description:Panicum hallii CRS.3.G3 Transcriptome - CRS.3.G3.S20_Illumina

| PRJNA1362273 | ENA

power plant metagenome

Project description:power plant metagenome Raw sequence reads

| PRJNA407460 | ENA

IFNgamma-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy

Project description:CAR-T (Chimeric antigen receptor T cell) therapy has led to significant improvements in patient survival. However, a subset of patients experience high-grade toxicities, including cytokine release syndrome (CRS) and immune cell-associated hematological toxicity (ICAHT). We utilized IL-2Ralpha knockout mice to model toxicities with elevated levels of IL-6, IFNgamma, and TNFalpha and increased M1-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils and a decrease in proliferative and mature neutrophils. Both non-tumor-bearing and Emu-ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNgamma-blockade alleviated CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive co-occurrence of CRS and neutropenia in an IFNgamma-dependent manner leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNgamma-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNgamma-blockade to reduce both CRS and neutropenia.

2025-09-17 | GSE308219 | GEO

Colon contents

Project description:Colon contents metagenome

| PRJNA772914 | ENA